Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
The Rigveda is one of the four oldest and most sacred collections of stories in Hinduism. In the Rigveda soma is a drink consumed by two of the main gods; Agni and Indra. In the texts, the drink helped the gods in battle by strengthening them physically. Because of this, soma was given and consumed by warriors before wartime or a battle. The drink was supposed to give the warriors strength and luck in the upcoming conflict. Immortality is also a quality associated with soma due to it being a drink of the divine. At religious ceremonies the drink was consumed to give consumers longevity in life. At birth the drink was also given to the babies for these same reasons. In Zoroastrianism, the drink is called haoma and has similar uses. Just like in Hinduism, the drink was related to immortality and long life. Haoma was the first thing newborns drank. This assured the child would be healthy and live a long life. The drink was also administered to people close to death to revive them back into good health. The physical appearance of Ephedra is also a reason it is believed to be the soma plant. According to the Vedic text Rigveda, the plant comprising soma is shaped like an arrow. Ephedra sinica is a gymnosperm that forms stalks with buds on the end. It is easy to see how this shape could be described as an arrow. Another text refers to soma as a twig, which is much like Ephedra sinica when it is dried out.
Elexacaftor and tezacaftor act as CFTR correctors to repair F508del processing by binding to the CFTR protein to increase the availability of CFTR protein on the cell surface. They work by modulating the position of the CFTR protein into the right position on the cell surface. Elexacaftor binds at a different site than tezacaftor. The combination of increased CFTR protein in the correct position on the cell surface with ivacaftor's potentiation of chloride channel opening results in increased transport of chloride and thinned mucus secretions.
The legion was probably founded by Diocletian to help defend the Danube. I Pontica: the legion was founded by Dioceltian to help defend Pontus Polemoniacus. The legion was stationed in Trapezus. Legio II II Armeniaca II Britannica: comitatensis under Magister Peditum II Flavia Constantia: comitatensis under the command of the Magister Peditum II Flavia Virtutis: comitatensis under the command of the Magister Peditum II Herculia (devoted to Hercules): levied by Diocletian, stationed in Scythia Minor II Isaura II Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum, in Comes Illyricum command. It was probably founded by Crispus or Constans. Its objective was to defend Alpes Cottiae II Felix Valentis Thebaeorum: comitatensis Legio III III Diocletiana III Flavia Salutis: comitatensis unit of the Late Roman Empire under the command of the Magister Militum in the west. The Legio III Flavia Salutis was raised by either Constantius II or Diocletian and was used to guard North Africa. III Herculea: comitatensis under the command of the Comes Illyricum III Isaura III Iulia Alpina: comitatensis under the command of the Magister Peditum command in Italy Legio IV IV Italica IV Martia IV Parthica Legio V V Iovia (maybe the Jovians) V Parthica Legio VI VI Gemella VI Gallicana VI Herculia (maybe the Herculians) VI Hispana VI Parthica Legio XII XII Victrix
==== Energy in QDs ==== In terms of energy, each individual quantum dot presents an energy level which is compared to that of an atom. Extending this property, an artificial lattice (made out of QDs) would have an energy band structure similar to the one of a crystalline semiconductor. The energy level of a dot is dependent on the amount of charge in it and its capacitance.The energy present in electrons is proportional to the square of the wavelength, which makes the energy levels to rise quickly
==== João Rouxinhol's lie ==== João Rouxinhol, one of the inspectors of the first investigation team of the PJ stated in court in 2012 that he lied to the press in 2005 when he accused Mendonça's family of having hidden the fact that Mendonça suffered from epilepsy. When questioned by the press about the following statement given in court he said that it doesn't match with a lie:"When I said it, I said it, the statement not being true. What I said about only knowing in 2005 about the epilepsy is not factually true, I gave that interview thrilled by some revolt that I felt for what was being said against our investigation team."The inspector received a light punishment of 25 days of suspension, replaced by loss of salary in retirement pension. João Rouxinhol also said that because of "forgetfulness" he did not listen to the witness Alcina Dias. Other crucial witnesses were heard years after the disappearance and by another investigation team. One of them a merchant that said he saw Alcina Dias with a boy.
Sources: en.wikipedia.org
== Clinical significance == Polymorphisms in ACTC1 have been linked to dilated cardiomyopathy in a small number of Japanese patients. Further studies in patients from South Africa found no association. The E101K missense mutation has been associated with hypertrophic cardiomyopathy and left ventricular noncompaction. Another mutation has in the ACTC1 gene has been associated with atrial septal defects.
== History == Fentanyl was first synthesized in Belgium by Paul Janssen under the label of his relatively newly formed Janssen Pharmaceutica in 1959. It was developed by screening chemicals similar to pethidine (Demerol) for opioid activity. The widespread use of fentanyl triggered the production of fentanyl citrate (the salt formed by combining fentanyl and citric acid in a 1:1 stoichiometric ratio). Fentanyl citrate entered medical use as a general anesthetic in 1968, manufactured by McNeil Laboratories under the brand name Sublimaze. In the mid-1990s, Janssen Pharmaceutica developed and introduced into clinical trials the Duragesic patch, which is a formulation of an inert alcohol gel infused with select fentanyl doses, which are worn to provide constant administration of the opioid over 48 to 72 hours. After a set of successful clinical trials, Duragesic fentanyl patches were introduced into medical practice.
== Similar terms for different quantities == The atomic mass or relative isotopic mass are sometimes confused, or incorrectly used, as synonyms of relative atomic mass (also known as atomic weight) or the standard atomic weight (a particular variety of atomic weight, in the sense that it is standardized). However, as noted in the introduction, atomic mass is an absolute mass while all other terms are dimensionless. Relative atomic mass and standard atomic weight represent terms for (abundance-weighted) averages of relative atomic masses in elemental samples, not for single nuclides. Relative atomic mass and standard atomic weight will only be the same as the relative isotopic mass for elements with one stable isotope. The atomic mass (relative isotopic mass) is defined as the mass of a single atom, which is only one isotope (nuclide), and is not an abundance-weighted average, as in the case of relative atomic mass/atomic weight. The atomic mass or relative isotopic mass of each isotope and nuclide of a chemical element is, therefore, a number that can be measured to high precision, since every specimen of such a nuclide is identical in mass to every other specimen, as all atoms of a given type in the same energy state, and every specimen of a particular nuclide, are identical in mass. For example, every atom of oxygen-16 has exactly the same atomic mass (relative isotopic mass).
The UK's first supermarket under the new Premier Supermarkets brand opened in Streatham, South London, taking in ten times as much revenue per week as the average British general store of the time. Other chains caught on quickly. The number of British supermarkets exploded from roughly 50 in 1950 to 572 by 1961, and finally to over 3,400 by 1969. After Galvani lost out to Tesco's Jack Cohen in 1960 to buy 212 stores of the Irwin's chain, the sector underwent significant consolidation, resulting in "the big four" dominant UK supermarket chains: Tesco, Asda, Sainsbury's and Morrisons. In the 1950s, supermarkets frequently issued trading stamps as incentives to customers. Today, most chains issue store-specific "membership cards", "club cards", or "loyalty cards". These typically enable the cardholder to receive special members-only discounts on certain items when the credit card-like device is scanned at the checkout. Sales of selected data generated by club cards is becoming a significant revenue stream for some supermarkets.
Sources: en.wikipedia.org
APEC Business Travel Card (ABTC): The APEC Business Travel Card, or ABTC, is an expedited border control programme for business travellers from APEC economies (excluding Canada and America). It provides visa exemptions and access to expedited border control facilities. ABTC holders are eligible for expedited border control at Canadian airports but not for any visa exemptions. ABTCs are generally issued only to citizens of APEC member countries; however, Hong Kong issues them to Permanent Residents who are not Chinese citizens, a category primarily consisting of British, Indian, and Pakistani citizens. The use of ABTCs in China is restricted due to the One Country, Two Systems and One China policies. Chinese nationals from Hong Kong, Macau, and the Republic of China are required to use special internal travel documents to enter the mainland. Similar restrictions apply to the use of ABTC by Chinese citizens from other regions entering areas administered by the Republic of China. (see: Internal border controls). Australia: SmartGates located at major Australian airports, allowing Australian ePassport holders and ePassport holders of several other countries to clear immigration controls more rapidly, and to enhance travel security by performing passport control checks electronically. SmartGate uses facial recognition system to verify the traveller's identity against the data stored in the chip in their biometric passport, as well as checking against immigration databases.
positive control Also positive regulation. The initiation, activation, or enhancement of some biological process by the presence of a specific molecular entity (e.g. an activator or inducer), in the absence of which the process cannot proceed or is otherwise diminished. In gene regulation, for example, the binding of an activating molecule such as a transcription factor to a promoter may recruit RNA polymerase to a coding sequence, thereby causing it to be transcribed. Contrast negative control.
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China. Azvudine was first discovered in 2007. It costs 350 Chinese yuan per 7 days for COVID, as of November 2022.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.